Augmentin 500mg is a mid‑range strength combination of amoxicillin and clavulanate designed to provide enhanced coverage against β‑lactamase–producing pathogens. Available as tablets, capsules, and oral suspension, it offers flexible administration for both adults and pediatric patients, with weight‑based mg/kg dosing detailed in the Pediatric section. This dosage is commonly selected for moderate respiratory and ENT infections, including sinusitis, otitis media, bronchitis, and community‑acquired pneumonia, as well as skin infections and animal bites where broader antimicrobial activity is clinically beneficial.
Compared with Augmentin 250mg, the 500mg strength delivers higher antibacterial activity suitable for more pronounced symptoms or infections requiring stronger β‑lactam coverage. At the same time, it maintains a lower gastrointestinal burden than 875mg, making it an appropriate choice for moderate cases where efficacy and tolerability must be balanced. Suspension‑based options are covered in the Suspension guide, while structured notes on adverse reactions and drug compatibility appear in the Side Effects and Interactions sections.
Augmentin 500mg is a mid‑strength formulation combining amoxicillin with clavulanate, a β‑lactamase inhibitor that expands antibacterial coverage against resistant community‑acquired pathogens. This balanced ratio makes the 500mg dose suitable for most outpatient infections where broader protection is required compared with standard aminopenicillins. As part of the wider Augmentin family (Augmentin overview), it maintains predictable absorption, reliable tissue penetration, and a well‑established clinical profile across adult and pediatric populations.
Clinically, Augmentin 500mg is used for respiratory and ENT infections such as acute sinusitis, otitis media, bronchitis, and mild to moderate community‑acquired pneumonia. It is also prescribed for skin and soft‑tissue infections, including cellulitis and animal bites, where β‑lactamase–producing organisms are common. The dosage is widely considered a “middle‑strength” option, offering stronger antibacterial activity than lower strengths while maintaining good gastrointestinal tolerability.
The 500mg strength is available in multiple oral forms — tablets, capsules, and suspension — supporting flexible use across age groups and clinical scenarios. Pediatric dosing follows mg/kg principles, allowing precise adjustment based on weight and infection severity. Overall, Augmentin 500mg serves as a dependable therapeutic choice for routine outpatient infections requiring enhanced β‑lactam coverage without escalating to higher‑dose regimens.
Augmentin 500mg is available in several oral formulations designed to support flexible dosing across outpatient care. The most common option is the 500mg tablet, a stable and predictable form frequently used in adult treatment pathways and covered in detail in the Tablets section. Capsules containing the same 500mg strength offer an alternative for patients who prefer smoother swallowing or require a different administration profile; these are outlined in the Capsules guide.
For pediatric patients and adults who need adjustable dosing, Augmentin suspension provides an equivalent 500mg dose when measured appropriately. This formulation allows precise titration based on weight and infection severity, making it especially useful in mg/kg‑based regimens. Detailed preparation, measurement, and dosing instructions are available in the Suspension section.
Across all forms, the 500mg strength is positioned as a mid‑range option suitable for moderate respiratory, ENT, and skin infections. Its availability in multiple formulations ensures broad applicability across age groups, swallowing preferences, and clinical scenarios, supporting consistent therapeutic outcomes in routine outpatient practice.
In adult patients, Augmentin 500mg is typically prescribed at a frequency of 2–3 times per day, depending on infection severity and clinical presentation. This mid‑strength regimen is widely used for moderate respiratory and ENT infections, including acute sinusitis, otitis media, bronchitis, and mild community‑acquired pneumonia. The 500mg dose provides enhanced β‑lactamase coverage compared with lower strengths while maintaining good gastrointestinal tolerability.
When symptoms intensify or when pathogens with higher resistance potential are suspected, clinicians often escalate therapy to the higher 875mg strength. This stronger option, described in the 875mg section, is typically reserved for severe infections requiring more robust antibacterial activity. The structured dosing progression helps balance efficacy with tolerability, ensuring patients receive adequate coverage without unnecessary GI burden.
| Strength | Frequency | Use |
|---|---|---|
| 250mg | 3×/day | Mild infections |
| 500mg | 2–3×/day | Moderate infections |
| 875mg | 2×/day | Severe infections |
Overall, the 500mg adult regimen remains a dependable middle‑tier option, offering sufficient potency for most outpatient infections while allowing escalation when clinical conditions warrant stronger therapy.
Pediatric dosing for Augmentin follows weight‑based mg/kg principles to ensure precise therapeutic coverage across varying infection severities. Standard outpatient regimens typically range from 40–45 mg/kg/day, divided into 2–3 doses to maintain stable serum concentrations. This range is appropriate for mild to moderate respiratory and ENT infections, including otitis media and sinusitis. Detailed pediatric guidance is provided in the Pediatric section.
In more severe cases — such as complicated otitis media, refractory sinusitis, or pneumonia with higher resistance risk — dosing may increase to 80–90 mg/kg/day. This high‑dose strategy enhances β‑lactamase coverage and improves outcomes in infections caused by less susceptible organisms. Dividing the total daily dose into 2–3 administrations helps maintain therapeutic levels while minimizing gastrointestinal discomfort.
Suspension formulations play a key role in pediatric dosing because they allow precise measurement of mg/kg amounts. By adjusting milliliters rather than fixed tablet strengths, clinicians can tailor therapy to the child’s exact weight, improving accuracy and adherence.
| Weight (kg) | Daily Dose (mg) | Per Dose (mg) |
|---|---|---|
| 10 kg | 400–900 mg | 200–300 mg |
| 15 kg | 600–1350 mg | 300–450 mg |
| 20 kg | 800–1800 mg | 400–600 mg |
These structured mg/kg ranges ensure safe, effective, and individualized therapy across pediatric age groups, supporting predictable outcomes in routine outpatient infection management.
Augmentin 500mg is widely prescribed for moderate community‑acquired infections where enhanced β‑lactamase coverage is required. One of its most common uses is acute bacterial sinusitis, particularly in patients presenting with persistent symptoms or inadequate response to lower‑strength regimens. It is also a standard option for acute otitis media, offering reliable activity against resistant middle‑ear pathogens.
In respiratory infections, Augmentin 500mg is frequently used for uncomplicated bronchitis and mild to moderate community‑acquired pneumonia. Its combination of amoxicillin and clavulanate provides broader coverage than aminopenicillins alone, making it suitable for outpatient management of cases where β‑lactamase–producing organisms are suspected.
Beyond ENT and respiratory indications, Augmentin 500mg is effective for mild to moderate skin infections, including cellulitis and early abscesses. It is also a first‑line therapy for animal bites, where mixed aerobic and anaerobic flora — including Pasteurella species — require broad antimicrobial coverage. Overall, the 500mg strength offers a balanced profile suitable for a wide range of moderate infections across outpatient care.
Augmentin dosing is structured around infection severity, with each strength serving a distinct clinical role. The 250mg formulation is typically used for mild infections, early ENT presentations, and pediatric cases where mg/kg adjustments are required. It provides adequate coverage with lower clavulanate exposure, improving gastrointestinal tolerability.
The 500mg strength represents the standard option for moderate infections, offering stronger antibacterial activity while maintaining a manageable GI profile. It is commonly selected for sinusitis, otitis media, bronchitis, and mild pneumonia. For more severe presentations, clinicians often escalate therapy to the high‑strength 875mg formulation, which delivers greater amoxicillin exposure and improved suppression of resistant pathogens.
| Strength | Best Use | Notes |
|---|---|---|
| 250mg | Mild infections | Pediatric/Adults |
| 500mg | Moderate infections | Standard adult dose |
| 875mg | Severe infections | High-strength |
This tiered structure helps clinicians match dosing intensity with clinical need, ensuring optimal efficacy while minimizing unnecessary clavulanate exposure.
Augmentin 500mg is generally well tolerated, but its safety profile is influenced by the clavulanate component, which is associated with gastrointestinal reactions such as nausea, abdominal discomfort, and diarrhea. These effects are dose‑dependent, meaning higher strengths may increase GI burden. A structured overview of common reactions is available in the Augmentin side effects section.
Allergic reactions remain an important consideration, particularly in individuals with a history of penicillin or β‑lactam allergy. Symptoms may include rash, pruritus, or more severe hypersensitivity responses. Patients with known allergies should review guidance in the Penicillin allergy section before initiating therapy.
Dermatologic reactions such as mild rash can occur, especially in pediatric patients or during viral illnesses. While many rashes are benign, distinguishing between allergy‑related and non‑allergic skin reactions is essential for safe continued use. Overall, Augmentin 500mg maintains a favorable safety profile when used appropriately and with attention to individual risk factors.
Augmentin 500mg has several clinically relevant drug interactions that may influence dosing, monitoring, or therapeutic decisions. One of the most important is its interaction with warfarin: co‑administration may increase INR due to alterations in gut flora and vitamin K metabolism, requiring closer anticoagulation monitoring. Structured guidance on these interactions is available in the Augmentin interactions section.
Allopurinol is another agent that may interact with Augmentin. When used together, the risk of rash can increase, particularly in patients with underlying renal impairment or high‑dose aminopenicillin therapy. Although not dangerous in most cases, clinicians typically monitor for dermatologic reactions during combined use.
Probenecid can significantly affect Augmentin pharmacokinetics by reducing renal tubular secretion of amoxicillin, leading to higher and more prolonged serum levels. This interaction may be intentionally used in certain therapeutic contexts, but in routine outpatient care it is generally avoided to prevent excessive drug exposure.
Proper storage of Augmentin 500mg ensures stability, potency, and safe use across all formulations. Tablets and capsules should be kept at standard room temperature, ideally in a dry environment away from direct sunlight and moisture. This helps maintain structural integrity and prevents degradation of both amoxicillin and clavulanate components. These solid forms are generally stable throughout their labeled shelf life when stored correctly.
Suspension requires more careful handling. Once reconstituted, it must be stored in the refrigerator to preserve potency and prevent microbial growth. Most Augmentin suspensions remain stable for 7–10 days, after which any remaining product should be discarded. Detailed preparation and storage instructions are provided in the Suspension section.
Regardless of formulation, Augmentin should always be kept out of reach of children and used only within prescribed timeframes. Following proper storage guidelines helps ensure consistent therapeutic performance and minimizes the risk of reduced efficacy due to improper handling.